Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875159 | 1.00 | ALDH1A1 (0.49) | ALDH1A1MAPTHPGDLMNATP53 | |
| SCHEMBL29875151 | 0.85 | MTNR1A (0.47) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL19926108 | 0.85 | MTNR1A (0.47) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL19926023 | 0.79 | FFAR1 (0.56) | ALDH1A1MAPTSMN1; SMN2HTTFFAR1 | |
| SCHEMBL19926028 | 0.78 | MAPT (0.49) | ALDH1A1MAPTHPGDLMNATP53 | |
| SCHEMBL29875283 | 0.78 | MAPT (0.49) | ALDH1A1MAPTHPGDLMNATP53 | |
| SCHEMBL30665930 | 0.77 | TTR (0.54) | ALDH1A1MAPTHPGDLMNATP53 | |
| SCHEMBL1736331 | 0.77 | TTR (0.54) | ALDH1A1MAPTHPGDLMNATP53 | |
| SCHEMBL1733997 | 0.76 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDLMNATP53 | |
| SCHEMBL7825236 | 0.76 | CYP19A1 (0.62) | ALDH1A1MAPTHPGDLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| CN-109890822-B | Inhibitors of cellular metabolic processes | 安吉奥斯医药品有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2019-08-01 | — | — | US | disclosed |
| EP-3507290-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | Agios Pharmaceuticals, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10329298-B2 | Inhibitors of cellular metabolic processes | AGIOS PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
| WO-2018045071-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | AGIOS PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329298-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | ALDH1A1 352/4885MAPT 1914/4885HPGD 2425/4885 |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | ALDH1A1 352/4885MAPT 1914/4885HPGD 2425/4885 |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | ALDH1A1 352/4885MAPT 1914/4885HPGD 2425/4885 |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | ALDH1A1 352/4885MAPT 1914/4885HPGD 2425/4885 |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | ALDH1A1 352/4885MAPT 1914/4885HPGD 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.